company background image
SOLARAPP1 logo

Solara Active Pharma Sciences NSEI:SOLARAPP1 Stock Report

Last Price

₹345.90

Market Cap

₹23.0b

7D

29.3%

1Y

n/a

Updated

25 May, 2025

Data

Company Financials +

Solara Active Pharma Sciences Limited

NSEI:SOLARAPP1 Stock Report

Market Cap: ₹23.0b

SOLARAPP1 Stock Overview

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. More details

SOLARAPP1 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance3/6
Financial Health2/6
Dividends0/6

Rewards

Trading at 61.1% below our estimate of its fair value

Earnings are forecast to grow 72.24% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Interest payments are not well covered by earnings

Shareholders have been substantially diluted in the past year


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Solara Active Pharma Sciences Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Solara Active Pharma Sciences
Historical stock prices
Current Share Price₹345.90
52 Week High₹554.95
52 Week Low₹200.00
Beta1.12
1 Month Change29.33%
3 Month Change52.61%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO61.75%

Recent News & Updates

Here's Why Solara Active Pharma Sciences (NSE:SOLARAPP) Can Manage Its Debt Responsibly

May 23
Here's Why Solara Active Pharma Sciences (NSE:SOLARAPP) Can Manage Its Debt Responsibly

Solara Active Pharma Sciences Limited (NSE:SOLARAPP) Could Be Riskier Than It Looks

Jan 25
Solara Active Pharma Sciences Limited (NSE:SOLARAPP) Could Be Riskier Than It Looks

Recent updates

Here's Why Solara Active Pharma Sciences (NSE:SOLARAPP) Can Manage Its Debt Responsibly

May 23
Here's Why Solara Active Pharma Sciences (NSE:SOLARAPP) Can Manage Its Debt Responsibly

Solara Active Pharma Sciences Limited (NSE:SOLARAPP) Could Be Riskier Than It Looks

Jan 25
Solara Active Pharma Sciences Limited (NSE:SOLARAPP) Could Be Riskier Than It Looks

Solara Active Pharma Sciences Limited (NSE:SOLARAPP) Soars 38% But It's A Story Of Risk Vs Reward

Sep 19
Solara Active Pharma Sciences Limited (NSE:SOLARAPP) Soars 38% But It's A Story Of Risk Vs Reward

We Think Solara Active Pharma Sciences (NSE:SOLARAPP) Has A Fair Chunk Of Debt

Aug 24
We Think Solara Active Pharma Sciences (NSE:SOLARAPP) Has A Fair Chunk Of Debt

Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARAPP) Revenues Despite 55% Price Jump

Jul 28
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARAPP) Revenues Despite 55% Price Jump

Shareholder Returns

SOLARAPP1IN PharmaceuticalsIN Market
7D29.3%-0.04%-0.2%
1Yn/a13.1%2.2%

Return vs Industry: Insufficient data to determine how SOLARAPP1 performed against the Indian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SOLARAPP1 performed against the Indian Market.

Price Volatility

Is SOLARAPP1's price volatile compared to industry and market?
SOLARAPP1 volatility
SOLARAPP1 Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement7.0%
10% most volatile stocks in IN Market9.6%
10% least volatile stocks in IN Market4.7%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine SOLARAPP1's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20172,156Sandeep Raowww.solara.co.in

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antifungal, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support.

Solara Active Pharma Sciences Limited Fundamentals Summary

How do Solara Active Pharma Sciences's earnings and revenue compare to its market cap?
SOLARAPP1 fundamental statistics
Market cap₹22.95b
Earnings (TTM)₹5.40m
Revenue (TTM)₹12.84b
4,251x
P/E Ratio
1.8x
P/S Ratio

Is SOLARAPP1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SOLARAPP1 income statement (TTM)
Revenue₹12.84b
Cost of Revenue₹6.26b
Gross Profit₹6.57b
Other Expenses₹6.57b
Earnings₹5.40m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin51.21%
Net Profit Margin0.042%
Debt/Equity Ratio70.7%

How did SOLARAPP1 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/25 05:44
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Solara Active Pharma Sciences Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAntique Stockbroking Ltd.
Rishabh KaleIndsec Securities & Finance Ltd.
Alankar GarudeMacquarie Research